[{"id":"971d9282-8be3-4d0b-a747-485b598d1a88","acronym":"","url":"https://clinicaltrials.gov/study/NCT03006302","created_at":"2024-01-03T19:17:30.474Z","updated_at":"2025-02-25T16:05:38.933Z","phase":"Phase 2","brief_title":"Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer","source_id_and_acronym":"NCT03006302","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" STAT6","pipe":"","alterations":" ","tags":["STAT6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • epacadostat (INCB024360) • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 01/31/2018","start_date":" 01/31/2018","primary_txt":" Primary completion: 08/22/2023","primary_completion_date":" 08/22/2023","study_txt":" Completion: 08/05/2024","study_completion_date":" 08/05/2024","last_update_posted":"2024-10-08"},{"id":"5d5babd2-7c3c-4130-a0da-f4352113269f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02243371","created_at":"2021-01-18T10:31:41.476Z","updated_at":"2025-02-25T14:34:56.150Z","phase":"Phase 2","brief_title":"GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab","source_id_and_acronym":"NCT02243371","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • CRS-207 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 01/02/2015","start_date":" 01/02/2015","primary_txt":" Primary completion: 07/21/2017","primary_completion_date":" 07/21/2017","study_txt":" Completion: 07/21/2017","study_completion_date":" 07/21/2017","last_update_posted":"2021-04-06"},{"id":"ed9b78d3-4dd2-490d-a6a7-40b8f9a2f10e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01675765","created_at":"2021-01-18T07:15:14.071Z","updated_at":"2025-02-25T15:52:57.503Z","phase":"Phase 1b","brief_title":"Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT01675765","lead_sponsor":"Aduro Biotech, Inc.","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • cyclophosphamide • pemetrexed • CRS-207 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 09/03/2014","start_date":" 09/03/2014","primary_txt":" Primary completion: 09/05/2018","primary_completion_date":" 09/05/2018","study_txt":" Completion: 08/19/2019","study_completion_date":" 08/19/2019","last_update_posted":"2020-09-30"}]